Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago.

Viridian Therapeutics ( (VRDN)) has issued an update. Viridian Therapeutics, a biotech company, highlights its recent advancements in treating thyroid eye disease (TED) and FcRn inhibitor ...

Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN ...

Social Security recipients, including the roughly 1.5 million living in Arizona, will receive a 2.5% cost-of-living adjustment, or COLA, starting in 2025, raising the average monthly benefit by ...

We gain an hour of sleep for shorter daylight and longer nighttime hours. Adjusting our clocks an hour forward may not seem like a huge deal, but experts have explained that the time change can ...

Viridian Advisory’s Brett Arnol has detailed how the firm is fostering the next generation of advisers through its Professional Year (PY) program. Viridian was established in 2015 and has more than ...

The big challenge for retirees is that they're still reeling from the high inflation experienced in 2021 and 2022, which was reflected in the COLAs for the following years. Those years top the ...

A newly developed air defense laser has 100 percent of incoming threats during a new trial, the U.K. government has said, as several militaries forge ahead with efforts to get lasers operational ...

As inflation has cooled down, taxpayers can expect to see relatively slight changes ahead in the annual inflation adjustment for tax brackets and some tax breaks for 2025. The Internal Revenue ...

“We, the patent community…should work together to incrementally improve our system and find and fix rules that are not working as intended.” Patent Term Adjustment (PTA) is a statutory right ...